West Pharmaceutical Services Reports Strong Q2 Results and Raises Full-Year Guidance
West Pharmaceutical Services (NYSE:WST) reported second-quarter results that exceeded expectations, with revenue rising 13% organically to $872 million. Adjusted earnings per share increased by 29% year-over-year to $2.37. The company raised its full-year guidance for both revenue and adjusted EPS due to strong demand in biologics, GLP-1 elastomers, and high-value product components. The High-Value Product (HVP) segment was the primary growth driver, contributing 49% of total revenue with $424 million generated from HVP components. The Proprietary Products segment saw a 16% organic increase in sales, driven by biologics and biosimilars demand. CEO Eric Green attributed the strong performance to strategic execution, operational excellence initiatives, and recovery following a cyber incident during the quarter. CFO Bob McMahon highlighted ongoing momentum from Annex 1-related upgrades as well as continued strength in GLP-1 elastomers.
Tickers: $WST
Topics: biologics GLP-1 elastomers high-value products pharmaceutical revenue growth